the other big reason is clinical trials. if you can identify people who are pre-symptomatic but on a trajectory toward Alzheimer's, you can actually test whether early interventions work. that's been one of the big blockers for drug development -- by the time people show symptoms, they're often too far along for treatments to show effect. a reliable blood test changes the trial design fundamentally.